-
Uterine leiomyosarcomas (LMS) rarely are suspected preoperatively unless there has been documented rapid growth of the uterus or evidence of extrauterine disease.
-
Dealing with a question about certain dietary items in pregnancy sometimes is daunting because often there is no consensus regarding a proper answer.
-
Baseline and 6-month data were collected on morbidly obese women who planned to undergo weight reduction surgery.
-
In this issue: Two new drugs for treatment of hepatitis C; NSAIDs and myocardial infarction risk; AIM-HIGH clinical trial stopped; and FDA actions.
-
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.
-
For four decades, safety-net providers such as community health centers have turned to the National Health Service Corps (NHSC) for help with maintaining a well-trained and credentialed workforce.
-
One woman in five develops a urinary tract infection (UTI) during her lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
-
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test.
-
A just-published study indicates that many providers are failing to counsel women on the availability of emergency contraception (EC).
-
Results of two case-control studies indicate that women without risk factors for venous thromboembolism (VTE) who use oral contraceptives (OCs) containing drospirenone have an increased risk for nonfatal VTE compared with those who use levonorgestrel OCs.